Protein C zymogen in adults with severe sepsis or septic shock
Med. intensiva (Madr., Ed. impr.)
; 38(5): 278-282, jun.-jul. 2014. ilus, tab
Article
en En
| IBECS
| ID: ibc-126393
Biblioteca responsable:
ES1.1
Ubicación: BNCS
RESUMEN
INTRODUCTION:
Activated protein C is associated with a risk of bleeding and its effects on survival in septic shock patients are questionable. Protein C zymogen has no risk of bleeding and improves the outcome of patients with septic shock. We hereby describe the largest published case series of adult patients receiving protein C zymogen. Design, setting andparticipants:
A prospective study on 23 adult patients with severe sepsisor septic shock, two or more organ failures and at high risk for bleeding, treated with protein C zymogen (50 IU/kg bolus followed by continuous infusion of 3 IU/kg/h for 72 h).RESULTS:
The Z-test evidenced a significant reduction between the expected mortality (53%)and the observed mortality 30% (Z value = 1.99, p = 0.046) in our sample population. Protein Clevels increased from 34 ± 18% to 66 ± 22% at 6 h after PC bolus (p < 0.001), and kept on increasing during 72 h of administration (p < 0.001 to baseline). Sequential Organ Failure Assessment(SOFA), score of organ dysfunction, decreased from baseline to 7 days after administration of protein C from 14 ± 2 to 7 ± 4 (p < 0.001). No adverse event drug related was noted.CONCLUSION:
Protein C zymogen administration is safe and its use in septic patients should be investigated through a randomized controlled trial
Texto completo:
1
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Choque Séptico
/
Proteína C
/
Sepsis
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Med. intensiva (Madr., Ed. impr.)
Año:
2014
Tipo del documento:
Article